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Neurobiology of Disease
The Role of Attenuated Astrocyte Activation in Infantile
Neuronal Ceroid Lipofuscinosis
Shannon L. Macauley,1Milos Pekny,3 andMark S. Sands1,2
Departments of 1Internal Medicine and 2Genetics, Washington University School of Medicine, St. Louis, Missouri 63110, and 3Center for Brain Repair and
Rehabilitation, Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University
of Gothenburg, 41390 Gothenburg, Sweden
Infantile neuronal ceroid lipofuscinosis (INCL) is an inherited neurodegenerative disorder affecting the CNS during infancy. INCL is
caused by mutations in the CLN1 gene that lead to a deficiency in the lysosomal hydrolase, palmitoyl protein thioesterase 1 (PPT1). A
murine model of INCL, the PPT1-deficient (PPT1/) mouse, is an accurate phenocopy of the human disease. The first pathological
change observed in thePPT1/ brain is regional areas of glial fibrillary acidic protein (GFAP) upregulation, which predicts future areas
of neurodegeneration. We hypothesized that preventing GFAP and vimentin upregulation in reactive astrocytes will alter the CNS
disease. To test this hypothesis, we generatedmice simultaneously carrying null mutations in theGFAP,Vimentin, and PPT1 genes
(GFAP/Vimentin/PPT1/). Although the clinical and pathological features of the GFAP/Vimentin/PPT1/ mice are
similar to INCL, the disease appears earlier and progresses more rapidly. One mechanism underlying this accelerated phenotype is a
profound neuroinflammatory response within the CNS. Thus, our data identify a protective role for intermediate filament upregulation
during astrocyte activation in INCL, a model of chronic neurodegeneration.
Introduction
Infantile neuronal ceroid lipofuscinosis (INCL), or Batten dis-
ease, is an autosomal-recessive, lysosomal storage disease affect-
ing the CNS (Kohlschu¨tter et al., 1993; Hofmann et al., 1999).
Caused by a deficiency in palmitoyl protein thioesterase 1 (PPT1)
(Vesa et al., 1995; Hofmann et al., 2001), INCL patients are
asymptomatic at birth and develop normally until they present
with visual impairments, seizures, cognitive deficits, and motor
dysfunction. Death occurs by 6 years (Santavuori et al., 1973;
Santavuori et al., 1974). Pathological findings include autofluo-
rescent storage material, glial activation, brain atrophy, cortical
thinning, neuronal loss, and demyelination (Haltia et al.,
1973a,b). A PPT1-deficient (PPT1/) mouse model was gener-
ated by disrupting theCLN1 gene (Gupta et al., 2001) andmimics
the cellular pathology and functional deficits observed in INCL
patients (Bible et al., 2004; Griffey et al., 2004, 2005, 2006; Kielar
et al., 2007; Macauley et al., 2009).
Previous studies demonstrated that localized regions of in-
creased expression of an intermediate filament protein glial
fibrillary acidic protein (GFAP) expression are the first patholog-
ical changes observed in the PPT1/ brains (Kielar et al., 2007;
Macauley et al., 2009). These regions also suffer the greatest neu-
ronal loss and atrophy as the disease progresses. We hypothesize
that the upregulation of intermediate filament proteins in reac-
tive astrocytes plays an active role in the pathogenesis of INCL.
The role of intermediate filament upregulation is an incom-
pletely understood phenomenon in CNS disease (Kalman, 2004;
Pekny and Nilsson, 2005; Sofroniew, 2005). Although GFAP
upregulation is a common indicator of reactive astrocytes, the rela-
tionship between increased intermediate filament protein expres-
sion(i.e.,GFAP,vimentin, andnestin)duringastrocytehypertrophy
and functional changesat themolecular level remainsunclear.Given
the elaborate set of functions associated with reactive astrocytes, we
and others described astrocyte activation as both a gain and loss of
function phenomenon resulting in favorable and deleterious effects
to an injured CNS, based on data gathered from numerous trans-
genic mouse studies (Pekny and Nilsson, 2005; Sofroniew et al.,
2009; Sofroniew and Vinters, 2010). Mice deficient in astrocyte in-
termediate filament proteins, GFAP and vimentin (Vim), address
the relationship between structural alterations and functional
changes associated with astrocyte activation, and report both posi-
tive (e.g., axonal sprouting, synaptic regeneration, faster wound
healing, decreased immune cell infiltration) and negative (e.g., dis-
rupted glial scars, larger infarct volumes, increased cell death) out-
comes when challenged (Pekny et al., 1995, 1999; Lane and Pekny,
2004; Lundkvist et al., 2004;PeknyandPekna, 2004;Nakazawaet al.,
2007; Li et al., 2008; Verardo et al., 2008). Thus, it is difficult to
predict what role GFAP upregulation in the CNS plays in INCL.
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For the purposes of our studies, we used mice deficient in
GFAP and Vimentin (GFAP/Vim/) as a model of attenu-
ated astrocyte activation. By crossing theGFAP/Vim/mice
with the PPT1/ mice, we were able to study the role of atten-
uated astrocyte activation in INCL. In the GFAP/Vim/
PPT1/ brains, the course of disease is exacerbated compared
with PPT1/mice.Mechanisms responsible for this accelerated
phenotype include immune cell infiltration and cytokine upregu-
lation. These data suggest that astrocyte activation plays a protec-
tive role in INCL.
Materials andMethods
GFAP/Vim/PPT1/mice.The individualGFAP/Vim/ and
PPT1/ mice were created as previously reported (Colucci-Guyon et
al., 1994; Pekny et al., 1995, 1999; Eliasson et al., 1999; Gupta et al., 2001;
Griffey et al., 2005). TheGFAP/Vim/micewere of amixedC57BL/
6/129SV/129Ola background, and the PPT1/mice were of a congenic
C57BL/6 background. The homozygous GFAP/Vim/ mice were
crossed with the homozygous PPT1/mice for the first initial mating.
The heterozygous progeny (GFAP/Vim/PPT1/) of the initial
mating were backcrossed to the PPT1/ background for two additional
generations, producing an 88% C57BL/6 background. Then, the
heterozygous GFAP/Vim/PPT1/ offspring were intercrossed to
ultimately generate all four groups (GFAP/Vim/PPT1/,GFAP/
Vim/,PPT1/, andWT).For thepurposesofour studies, themicewere
all generationally matched and maintained as four distinct homozygous
lines. The only exception was that the silver degeneration staining was per-
formed on PPT1/ and WT mice with a congenic C57BL/6 background.
All mice were maintained at Washington University School of Medicine.
Mouse genotypes were determined by PCR-based assays. Both male and
female mice from each genotype were used in this study. Animals were
housed under a 12 h light/dark cycle and were provided food and water ad
libitum. All procedures were performed under an approved Institutional
Animal Care and Use Committee protocol from Washington University
School of Medicine.
Longevity. GFAP/Vim/PPT1/, GFAP/Vim/, PPT1/,
and WT mice (n  10–18 mice per genotype) were used to assess lifes-
pan. Mice from each group were allowed to age, unmanipulated, under
the conditions described above. The end of life was signaled by either
death or a predetermined moribund condition. Kaplan–Meier analysis
was used tomeasure cumulative survival and determine differences (p
0.05) in lifespan.
Brain weights. The 3-, 5-, and 6-month-old GFAP/Vim/
PPT1/, GFAP/Vim/, PPT1/, and WT mice (n  5–6 mice/
genotype/age) were killed via an overdose of euthasol, and the brains
were harvested by a researcher blinded to both age and genotype. A razor
bladewas inserted coronally between the forebrain and olfactory bulbs to
remove the olfactory bulbs from the remainder of the brain. Similarly, a
coronal cut wasmade immediately posterior to the cerebellum to remove
the medulla and spinal cord from the forebrain and cerebellum. Each
brain was weighed. Differences in weights were analyzed with one-way
ANOVAs followed by Bonferroni’s correction post hoc tests.
Autofluorescent accumulation. Six-month-old GFAP/Vim/
PPT1/, GFAP/Vim/, PPT1/, and WT mice (n 3 mice per
group) were used to quantify autofluorescent accumulation in the so-
matosensory barrel field (S1BF) cortex using epifluorescent microscopy
(Bible et al., 2004; Kielar et al., 2007). Briefly, mice were given an over-
dose of euthasol, and the brains were removed and fixed for 48 h in 4%
PFA in phosphate buffer. Following fixation, the brains were cryopro-
tected in 30% sucrose, embedded in optimal cutting temperature com-
pound (OCT; Sakura), and sectioned coronally on a freezing cryostat at
20mthickness. Images from three serial sections through S1BF for each
group were captured via a 20 objective and FITC filter on a Nikon
microscope with a SPOT camera attached. All variables associated with
image capture, including exposure time, binning, and gain, were held
constant for all groups. Using ImageJ software, threshold analysis was
performed to determine which pixels contained autofluorescent accu-
mulation in a given image. The percentage of pixels containing autofluo-
rescent material was calculated for each image and reported as the area
fraction. Three sets of area fractionmeasurementswere captured for each
of the three sections through S1BF in each of the four groups. The average
for each group was calculated. Differences in autofluorescent accumula-
tion were analyzed using a one-way ANOVA followed by Bonferroni’s
correction post hoc test.
Nissl staining. Nissl staining was performed on 6-month-old GFAP/
Vim/PPT1/, GFAP/Vim/, PPT1/, and WT mice (n  3
mice per group). Briefly, mice were given a lethal injection of euthasol,
the brains removed, fixed for 48 h in 4% PFA in phosphate buffer, cryo-
protected in 30% sucrose, embedded inOCT, and sectioned coronally on
a freezing cryostat at 20 m thickness. Sections throughout the primary
visual cortex (V1) were mounted on glass slides, placed on a warming
plate for 1 h and allowed to thoroughly dry overnight at room tempera-
ture. Sections were briefly rinsed in distilled H2O (dH2O), incubated in
0.5% cresyl violet for 2 min, and rinsed with dH2O. The sections were
then dehydrated via a series of alcohols and xylenes, and coverslipped.
Cortical thickness. Cortical thickness measurements were performed
on Nissl-stained tissue from GFAP/Vim/PPT1/, GFAP/
Vim/, PPT1/ and WT brains (n  3 brains per group). Images
throughout V1 were captured at 10 magnification using an Olympus
BX41 microscope and Olympus DP 20 camera. Cortical thickness mea-
surements were made by an observer blinded to genotype from the
boundary of the white matter to the pial surface for each brain, as delin-
eated by Paxinos and Franklin (1997) and as previously described (Bible
et al., 2004; Kielar et al., 2007). A series of 10 individual measurements
was made for each of three sections for each mouse (n  3 mice per
group). For each mouse, the mean cortical thickness measurement for
each section was calculated, and statistical significance was performed by
a one-way ANOVA followed by Bonferroni’s correction post hoc test.
de Olmos cupric-silver staining. Three-, 5-, and 6-month-old GFAP/
Vim/PPT1/, GFAP/Vim/, PPT1/, and WT mice (n  2
per time point) were processed for de Olmos silver staining. Briefly, the
mice were deeply anesthetized with euthasol and transcardially perfused
with 4%paraformaldehyde in sodium cacodylate buffer. The brains were
removed and postfixed for 48 h. Each brain was embedded in a gelatin-
based matrix (Switzer, 2000), and serial coronal sections (35 m) were
made on a freezing microtome by Neuroscience Associates. Neuronal
degeneration was visualized by staining with a modified de Olmos
cupric-silver method (DeOlmos and Ingram, 1971; Switzer, 2000). A
matrix of brains at identical levels in the coronal plane was stained
simultaneously.
Blood–brain barrier permeability. Blood–brain barrier (BBB) integrity
was assessed in 5-month-oldWTandGFAP/Vim/PPT1/ (n 4
mice per group) using an Evan’s blue (EB) assay (Belayev et al., 1996;
Young et al., 2004). PPT1-deficient mice receiving a middle cerebral
artery occlusion (MCAO) served as a positive control.Micewere injected
with 2%Evan’s blue in saline via a tail vein injection (4l/g bodyweight).
After 30 min, the mice were transcardially perfused with PBS until both
the perfusate and liver were clear of blood (1–2 min). The brains were
removed, bisected sagittally, andweighed. One hemisphere was placed in
500 l of 50% TCA solution and homogenized for 1 min. Following
centrifugation, the dye was extracted and diluted 1:3 in EtOH. To deter-
mine the concentration of Evan’s blue dye in samples, the fluorescence
of each sample was determined by a fluorescent spectrophotometer
(F-2000, Hitachi; excitation of 620 nm and emission at 680 nm), and the
concentration was calculated based on external standards (100–500 ng/
ml) per gram of tissue. A one-way ANOVA was performed to determine
statistical significance at the p  0.05 level, with Tukey’s multiple-
comparison’s post hoc test.
Middle cerebral artery occlusion.Middle cerebral artery (MCA) occlu-
sionwas achieved using a nylon suture for 60min as described previously
(Belayev et al., 1996). Using an operating microscope, the left external
carotid artery (ECA) was exposed and loosely ligated with a 5–0 silk
suture through a midline neck incision in anesthetized mice. The distal
stump of the ECA and the branches to the proximal stump were electro-
coagulated. A 12 mm 6–0 surgical monofilament nylon suture was in-
troduced into the ECA stump, advanced 9–10 mm from the bifurcation
of the common carotid artery into the circle of Willis to occlude the
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ostium of the MCA to cause a 20% decrease in laser Doppler signal. The
6–0 silk suture ligating the proximal ECA was tightened to prevent
bleeding and immobilize the intraluminal suture inserted into theMCA.
Mice were transferred to an incubator (32°C) and allowed to recover
from anesthesia. After 60min, ischemia will be terminated by removal of
the intraluminal suture. Restoration of blood flow through the internal
carotid artery following removal of the intraluminal suture will be con-
firmed directly under an operatingmicroscope andmore distally by laser
Doppler (Miller et al., 2001; Gidday et al., 2005).
Immunohistochemistry. Six-month-old GFAP/Vim/PPT1/,
GFAP/Vim/, PPT1/, and WT mice were killed via an overdose
of euthasol and transcardially perfused with PBS until the liver was clear
of blood. The brains were removed and fixed in 4% paraformaldehyde in
phosphate buffer for 48 h, were cryoprotected with 30% sucrose in Tris-
buffered saline (TBS), and embedded in OCT. Brains were sectioned in
the coronal plane throughout the rostral–caudal axis using a freezing
cryostat. Adjacent, free-floating sections were incubated with the follow-
ing antibodies: rabbit anti-GFAP (1:500; Immunostar); rat anti-CD68
(1:500; AbD, Serotec); rat anti-CD31 [1:50; platelet endothelial cell ad-
hesionmolecule-1 (PECAM), BDPharMingen); rat anti-CD45 (1:50; BD
PharMingen); rabbit anti-CD3 (1:200; Laboratory Vision); and rabbit
anti-aquaporin 4 (AQP4; 1:1000; Millipore Bioscience Research Re-
agents). Briefly, sections were washed in TBS, incubated in 1% H2O2
(Sigma) to quench endogenous peroxidase activity, and rinsed thor-
oughly in TBS. The tissue was blocked for 1 h in 10% normal goat serum
(NGS; Sigma) and 0.25% Triton X-100 in TBS. Sections were incubated
overnight at 4°C with primary antibodies in 5% NGS and 0.2% Triton
X-100 in TBS. The following day the sections were rinsed in TBS and
incubated with secondary antibodies (1:500–1000, Vector Laboratories;
or 1:500, Invitrogen) in 10% NGS and 0.1% Triton X-100 in TBS for 75
min. The tissue was rinsed with TBS and then incubated with a
peroxidase-conjugated avidin–biotin complex (1:100; Vectastain Elite
ABC kit, Vector Laboratories) for 1 h at room temperature. Antibody
immunoreactivity was visualizedwith 3-3 diaminobenzidine andH2O2
(DAB kit, Vector Laboratories) in TBS. Sections were dehydrated and
coverslipped.
Quantitation for CD68-positive cells was performed in the S1BF cor-
tex of 6-month-old WT, GFAP/Vim/, PPT1/, and GFAP/
Vim/PPT1/ brains. Images through the S1BF were captured using
a 20 objective, Olympus BX41 microscope and Olympus DP 20 cam-
era. All variables associatedwith image capturewere held constant. Using
ImageJ software, images were converted to 8-bit grayscale, and threshold
analysis was used to identify CD68-positive cell bodies within the cortex.
Cell counts were performed on three sets of images taken per section, on
three sections total from three different brains per each genotype (n 4).
Statistical significance was calculated using a one-way ANOVA followed
by Tukey’s post hoc test.
To quantify CD3-positive cells, images were captured in the S1BF
cortex of 6-month-oldWT,GFAP/Vim/,PPT1/, andGFAP/
Vim/PPT1/ brains. Images through the S1BF were captured using
a 20 objective, Olympus BX41 microscope and Olympus DP 20 cam-
era, where all variables associated with image capture were held constant.
Manual cell counts were performed on three sets of images taken per
section, on three sections total from three different brains per each of
four genotypes. Statistical significance was calculated using a one-way
ANOVA followed by Tukey’s post hoc test.
Cytokine assays. To quantify the concentration of chemokines and
cytokines within the brain, a 14-biomarker Multi-Analyte Profile was
generated for 1-, 3-, and 6-month-old GFAP/Vim/PPT1/,
PPT1/, GFAP/Vim/, and WT mice by MYRIAD RBM using
standard Luminex technology. The 14 analytes included the following:
FGF-9, granulocyte-macrophage colony-stimulating factor (GM-CSF),
interferon- (IFN-), IFN--induced protein 10 [IP-10 (or CXCL10)],
lymphotactin (XCL1), macrophage inflammatory protein-1 [MIP-1
(or CCL4)], MIP-2 (CXCL1), monocyte chemotactic protein-1 [MCP-1
(or CCL2)], MCP-3 (or CCL7), MCP-5 (or CCL12), oncostatin-M,
RANTES [regulated upon activation, normal T-cell expressed and se-
creted (or CCL5)], and tumor necrosis factor- (TNF-). Briefly, mice
were transcardially perfused with PBS, and the brains were homogenized
in a solution consisting of 10mMTris, 150mMNaCl, 1mMdithiothreitol,
0.2% Triton, and 20 l/ml protease inhibitor cocktail (Sigma). The su-
pernatant from brain homogenates was diluted to obtain a protein target
concentration of 0.5–1.0 mg/ml and stored at70°C. Cytokine concen-
trations were quantified according to standard protocols at MYRIAD
RBM. A one-way ANOVA followed by Bonferroni’s post hoc tests was
used to determine significant changes in cytokine levels at each time
point.
Results
GFAP upregulation in the PPT1/mouse
GFAP upregulation, which precedes neuronal loss (Kielar et al.,
2007; Macauley et al., 2009), is one of the first histological
changes seen in the PPT1/ brain (Fig. 1a). Focal areas of GFAP
upregulation occur in the PPT1/ astrocytes beginning at 3
months of age (Fig. 1a, black arrows). Specifically, there is a no-
table increase in GFAP immunostaining throughout multiple
cortical, thalamic, and cerebellar regions inPPT1/mice. As the
mice age, there is a change in the intensity and distribution of
GFAP immunostaining throughout these regions as well as other
areas in the brain (blue arrows), including the hippocampus,
striatum, and brainstem.
At higher magnification, the GFAP-positive processes of im-
munostained astrocytes at 3 month of age appeared to surround
blood vessels (Fig. 1a, black arrows). However, as the mice age,
there appeared to be changes in GFAP immunoreactivity within
reactive astrocytes. By 5–7 months of age, the distribution of
GFAP immunostaining in individual cells appearedmore intense
and revealed more “star-shaped” protoplasmic astrocytes with
hypertrophied processes.
Another molecule often altered in reactive astrocytes concur-
rent with GFAP upregulation is AQP4, a prominent water chan-
nel localized to astrocytic endfeet.We performed double-labeling
experiments for AQP4 and the endothelial marker PECAM
(CD31), in the PPT1/ andWT brains at 7 months of age (Fig.
1b). In theWT brains, PECAM (CD31) immunostaining demar-
cated the vascular bed. AQP4 immunostaining inWT brains fol-
lowed the outline of the vasculature, consistent with localization
to the astrocytic endfeet. This pattern of stainingwas disrupted in
the PPT1/ brains. Moreover, immunostaining for AQP4 re-
sulted in amore diffuse pattern of staining where the localization
to astrocytic endfeet appeared to be less discrete.
Accelerated INCL phenotype inGFAP/Vim/PPT1/
mice
Both the GFAP/Vim/PPT1/ and PPT1/ mice experi-
enced premature death mimicking a clinical feature of INCL (Fig.
2). AllGFAP/Vim/PPT1/ and PPT1/mice died by 27
weeks and 35 weeks, respectively. Furthermore, the median sur-
vival for theGFAP/Vim/PPT1/micewas 23weeks of age
comparedwith33weeksforthePPT1/mice.Thus,theGFAP/
Vim/PPT1/mice died earlier than the PPT1/mice (p
0.001). No WT mice and only a single GFAP/Vim/mouse
(22 weeks) died prematurely in this study.
Brain weights were used as ameasure of overall brain atrophy.
The brains of both theGFAP/Vim/PPT1/ and PPT1/
mice developed normally with no difference in brain weights
observed at 3 months of age (Fig. 3a). However, by 5 months,
brain atrophywas apparent inboth theGFAP/Vim/PPT1/
and PPT1/mice (Fig. 3b). At 6months, there was a decrease in
the brain weights of theGFAP/Vim/PPT1/ (p 0.001),
GFAP/Vim/ (p  0.01), and PPT1/ mice (p  0.001)
compared with WT mice (Fig. 3c). The GFAP/Vim/
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PPT1/ and PPT1/ brains at 6 months decreased in weight
by 26.2 and 13.4%, respectively, when compared withWT brains
(p  0.01). The GFAP/Vim/PPT1/ brains weighed less
than the PPT1/ brains (14.8%decrease; p 0.01) at 6months.
Upon gross examination, V1 of GFAP/Vim/PPT1/
and PPT1/ mice appeared atrophied compared with WT
brains (Fig. 3d). Therefore, we measured cortical thickness in V1
at 6 months of age in the GFAP/Vim/PPT1/, GFAP/
Vim/, PPT1/, and WT mice (Fig. 3e). At 6 months of age,
there was a 28.9% decrease in cortical thickness of GFAP/
Vim/PPT1/ brains compared withWT, while the PPT1/
brains only suffered a 21.6% loss. Therefore, cortical thinning in
the GFAP/Vim/PPT1/ brains was more severe than in
the PPT1/ or GFAP/Vim/ brains.
Accumulation of autofluorescent material throughout the
neuraxis is a hallmark of INCL. To determine the level of storage
material in the CNS, we quantified autofluorescence in the S1BF
cortex of GFAP/Vim/PPT1/, GFAP/Vim/,
PPT1/, and WT brains (Fig. 3f). There was an increase (p 
0.001) in autofluorescent accumulation in both the GFAP/
Vim/PPT1/ and PPT1/ brains (3.3- and 2.6-fold
increase, respectively) when compared with WT or GFAP/
Vim/ brains. Furthermore, there was a 1.3-fold increase in the
levels of autofluorescent substrate in the GFAP/Vim/
PPT1/mice compared with the PPT1/mice (p 0.001).
Increased neurodegeneration in theGFAP/Vim/PPT1/
mice
Since neuronal loss is a hallmark of INCL, deOlmos cupric-silver
staining was performed to assess the extent of neurodegeneration
present in the GFAP/Vim/PPT1/ brains (Fig. 4). We
compared the severity of pathology in the GFAP/Vim/
Figure 1. Reactive astrocytes in the PPT/ brains. a, Focal regions of GFAP upregulation occur in the PPT1/ brain. GFAP upregulation is present in the thalamus, cortex, and cerebellum
beginning at 3 months (black arrows). By 5–7 months, the intensity and distribution of GFAP immunostaining increases (blue arrows). At high magnification in the V1, the first GFAP-positive
astrocytes observed at 3 months are associated with the vasculature (black arrows). As the PPT1/mice age, more star-shaped protoplasmic astrocytes demonstrate GFAP immunoreactivity.
Staining was absent in the 7-month-oldWT brains. b, Immunostaining for PECAM and AQP4 inWT and PPT1/ brains. PECAM immunostaining outlines the blood vessels in theWT V1, which is
closely associatedwith the AQP4 labeling of astrocytic endfeet. The pattern of AQP4 stainingwas disrupted in the PPT1/mice. The AQP4 stainingwas not limited to PECAM-positive vasculature
in the PPT1/mice.
Figure 2. Lifespan of the GFAP/Vim/PPT1/ mice. The GFAP/Vim/
PPT1/mice died earlier than the GFAP/Vim/, PPT1/, or WT mice (n 10–18
mice per genotype). Themedian lifespan forGFAP/Vim/PPT1/micewas 23weeks,
while that for the PPT1/mice was 33 weeks. Kaplan–Meier statistical analysis was used to
determine differences in lifespan at the p 0.05 level.
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PPT1/mice to the PPT1/,GFAP/Vim/, andWTmice
at 5 months of age (Fig. 4a,c). Little or no silver staining was
present in either the GFAP/Vim/ or WT brains. Con-
versely, the PPT1/ brains showed blackened cellular profiles
and axonal projections throughout the neuraxis, seen here in the
hippocampus, thalamus, and cortex (Fig. 4a). The same pattern
of staining was present in the GFAP/Vim/PPT1/ mice,
but the staining was more intense when compared with the
PPT1/mice. Higher-magnification images showed degenerat-
ing neurons within the cortex, thalamus, hippocampus, and cer-
ebellum of the GFAP/Vim/PPT1/ brains at 5 months of
age (Fig. 4b). In addition to the regional distribution of neurode-
generation, we also investigated the temporal progression of dis-
ease in theGFAP/Vim/PPT1/mice at 3, 5, and 6months
of age (Fig. 4c). As theGFAP/Vim/PPT1/mice age, there
is an increase in silver staining throughout the cortex, corpus
callosum, hippocampus, and thalamus. Although silver staining
is present in the cortex and thalamus at 3 months of age, the
hippocampus is relatively spared. As the mice age, darkly stained
profiles are apparent in the hippocampus as well as the cortex.
Similarly, staining in the corpus callosum increases in intensity by
5 months of age. By 6 months, the intensity of staining is more
intense than in a 7-month-old PPT1/ brain (Fig. 4c). In fact,
the intensity of staining in the 7-month-old PPT1/ brain is
comparable to a 5-month-old GFAP/Vim/PPT1/ brain.
Increased immune cell infiltration in
theGFAP/Vim/PPT1/mice
Sections of GFAP/Vim/PPT1/
brains stained withH&E displayed a small
cell infiltrate not present in the PPT1/,
GFAP/Vim/, or WT brains (data
not shown). Hypothesizing the small cell
infiltrate was composed of blood-derived
leukocytes,CD45 immunostaining, apan-
leukocyte marker, was performed in the
GFAP/Vim/PPT1/, GFAP/
Vim/, PPT1/, and WT brains (Fig.
5a). At 5 months of age, the GFAP/
Vim/PPT1/ mice appeared to have
more CD45-positive cells throughout
the brains compared with PPT1/ and
controls (Fig. 5a). No increase in CD45-
positive staining was seen in the GFAP/
Vim/ mice compared with WT animals
(data not shown).
At higher magnification, it was clear
that the CD45-positive cells within the
GFAP/Vim/PPT1/ brains were
morphologically diverse (Fig. 5b–d,
arrows). To ascertain what CD45 popu-
lations were present in the brain paren-
chyma, lineage-specific markers were
used to identify two distinct popula-
tions. First, anti-CD3 labeling identi-
fied T cells throughout the neuraxis in
both the GFAP/Vim/PPT1/ and
PPT1/ brains but not in the WT or
GFAP/Vim/ brains (Fig. 5e). There
was an increase in the number of CD3
cells in both the GFAP/Vim/
PPT1/ and PPT1/ brains compared
with GFAP/Vim/ or WT mice (p
0.01) (Fig. 5g). There was no difference in
the number of CD3 cells between GFAP/Vim/PPT1/
and PPT1/ brains. Interestingly, the greatest increase in im-
mune cells was observed in the monocyte population in the
GFAP/Vim/PPT1/ brains (Fig. 5f,h). Using an anti-
CD68 antibody to identify microglia and macrophages, a large
population of CD68-positive cells was observed in both the
PPT1/ and GFAP/Vim/PPT1/ brains (Fig. 5f ).
There was a 24% increase in the number of CD68-positive
profiles within the GFAP/Vim/PPT1/ brains com-
pared with the PPT1/ (Fig. 5h) (p 0.001). Neither theWT
nor GFAP/Vim/ brains had an appreciable monocyte
population within the brain.
Blood–brain barrier integrity of theGFAP/Vim/
PPT1/mice
To detect possible perturbations in the BBB, a quantitative EB
assay was used (Fig. 6). There was no significant difference (p
0.1798) in EB concentration in the GFAP/Vim/PPT1/
brains compared with WT mice, suggesting no gross perturba-
tion of the BBB in the GFAP/Vim/PPT1/ mice. There
was an increase (p 0.001) in EB concentrationwithin the brains
subjected to MCAO, a positive control for BBB disruption, com-
pared with the GFAP/Vim/PPT1/ or WT brains (Be-
layev et al., 1996).
Figure 3. Accelerated disease progression in the GFAP/Vim/PPT1/mice compared with PPT1/mice. a, Brain
weights at 3 months of age. There is no significant difference in brain weights among the GFAP/Vim/PPT1/, GFAP/
Vim/, PPT1/, and WT mice, suggesting that brain atrophy is an age-related loss and not a developmental defect (n
5–6).b, Brain atrophy begins at 5months in theGFAP/Vim/PPT1/ and PPT1/mice. There is a significant decrease
in brainweights in theGFAP/Vim/PPT1/ and PPT1/micewhen comparedwithWTmice.No change is observed in
the GFAP/Vim/ brains compared with WT brains (n  5–6 per group). c, Brain atrophy in the GFAP/Vim/
PPT1/ mice at 6 months. The GFAP/Vim/PPT1/ brains weighed significantly less than PPT1/, GFAP/
Vim/, and WT mice (n 5–6 per group). d, Cortical thinning in the GFAP/Vimentin/PPT1/ mice. Upon gross
examination of Nissl-stained tissue, V1 of GFAP/Vim/PPT1/ and PPT1/mice appeared atrophied compared with
GFAP/Vim/ and WT brains (n  3 per group). Scale bar, 100 m. e, Quantification of cortical thickness in the WT,
GFAP/Vim/, PPT1/, and GFAP/Vim/PPT1/mice. The visual cortex of GFAP/Vim/PPT1/mice
was significantly thinner than that of PPT1/, GFAP/Vim/, and WT mice (n 3 per group). Interestingly, all groups
displayed cortical thinning compared with WT brains (scale bar, 100 m). f, Autofluorescent accumulation in the GFAP/
Vimentin/PPT1/ and PPT1/ mice. There was an increase in autofluorescent material in the GFAP/Vim/
PPT1/ mice compared with PPT1/, GFAP/Vim/, and WT mice (n 3 per group). Only significant differences as
determined by one-way ANOVA followed by Bonferroni’s post hoc tests were highlighted on the graph: *p 0.05, **p 0.01,
***p 0.001.
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Elevated cytokine levels in theGFAP/Vim/PPT1/mice
A panel of 14 chemokines/cytokines was simultaneously evaluated
in 1-, 3-, and 6-month-old GFAP/Vim/PPT1/, PPT1/,
GFAP/Vim/, and WT brains. The cytokines can grossly be
divided into the following three groups based on function: (1) gen-
eralized proinflammatory molecules (Fig. 7a,d,g); (2) lymphocyte
and/ormonocyte activators (Fig. 7b,e,h); or (3)monocyte activators
(Fig. 7c,f,i). At 1month, there were increased concentrations of two
cytokines known to act on lymphocytes and/or monocytes, RAN-
TES and oncostatin-M, in the GFAP/Vim/PPT1/ brains,
but no changes were observed in either the GFAP/Vim/ or
PPT1/brains comparedwithWT(Fig. 7a–c). By 3months of age,
12 analytes displayed increased expression in either the GFAP/
Vim/PPT1/orPPT1/mice comparedwithWT(Fig. 7d–f).
Elevated levels of cytokine and chemokines (i.e., IFN-, TNF-,
oncostatin-M, lymphotactin, GM-CSF, RANTES, IP-10, MIP-1,
MIP-2, MCP-1, MCP-3, and MCP-5) were found in the GFAP/
Vim/PPT1/ mice compared with GFAP/Vim/ or WT
mice (p  0.001). Fewer cytokines and chemokines (i.e., IP-10,
MCP-1,MCP-3, andMCP5) were elevated in the PPT1/mice at
the same age comparedwith controls (p 0.001). Of themonocyte
activatorsMIP-2,MCP-1,MCP-3, andMCP-5, there was no signif-
icant difference in cytokine levels between the GFAP/Vim/
PPT1/ and PPT1/ mice. By 6 months of age, the PPT1/
brains had similar levels of nearly all the cytokines listed above com-
pared with GFAP/Vim/PPT1/ brains (Fig. 7g–i). Interest-
ingly, the concentrations of several cytokines in the PPT1/ brain
known to activate and recruit monocytes (Fig. 7i), including IP-10,
MCP-1,MCP-3, andMCP-5,werehigher than thatof agedmatched
GFAP/Vim/PPT1/mice.
Discussion
The first histopathological change observed in the PPT1/
mouse is the upregulation of the intermediate filament protein,
GFAP, in reactive astrocytes. GFAP upregulation was present as
early as 3 months of age in the thalamus, cortex, and cerebellum
Figure 4. Neurodegeneration in the GFAP/, Vimentin/, and PPT1/ mice. a, Comparison of silver staining at 5 months of age in the WT, GFAP/Vim/, PPT1/, and
GFAP/Vim/PPT1/mice. At 5 months of age, there was no staining within theWT or GFAP/Vim/ brains. Neurodegeneration in the PPT1/ brain (n 2) was localized to the
corpus callosum, hippocampus, and thalamus (arrows). In the GFAP/Vim/PPT1/ brain (n 2), staining in these regions appeared more intense, suggesting an accelerated disease
course (n 2per group). Scale bar, 300m.b, Representative images from the cortex, thalamus, hippocampus, and cerebellumof 5-month-oldGFAP/Vim/PPT1/mice. Darkly stained
cell bodies were present in the cortex (scale bar, 50m) and CA1 field of the hippocampus (scale bar, 50m), while degenerating axons are present in the thalamus (scale bar, 100m) and
cerebellarwhitematter tracts (scale bar, 50m). c, Time course of silver degeneration staining in theGFAP/Vim/PPT1/mice. As theGFAP/Vim/PPT1/mice age, there is an
increase in silver staining throughout the cortex, corpus callosum, hippocampus, and thalamus. Interestingly, the level of staining in a 7-month-old PPT1/ brain is comparable to that observed
in a 5-month-old GFAP/Vim/PPT1/ brain and is far less than that of a 6-month-old GFAP/Vim/PPT1/ brain. Scale bar, 300m.
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of PPT1/mice. Subsequent to this marker of early-stage astro-
cyte activation, there was significant neuronal loss in the same
regions (Kielar et al., 2007; Macauley et al., 2009). Therefore, we
hypothesized that astrocyte activation plays a role in the patho-
genesis of INCL. If so, are reactive astrocytes beneficial or detri-
mental to the INCL brain?
In the absence of the intermediate filament proteins, GFAP
and vimentin, the time course of disease was accelerated in the
GFAP/Vim/PPT1/ mice compared with the PPT1/
mice. By all criteria measured, the GFAP/Vim/PPT1/
mice displayed either an earlier onset of the disease (i.e., premature
death and brain atrophy) or an increased severity of disease at a
particular time point (i.e., cortical thinning, autofluorescence,
neurodegeneration, and immune cell infiltration). These data
suggest that intermediate filament upregulation associated with
reactive astrocytes, is a protective process in INCL. Although
reactive astrocytes are responsible for both positive and negative
outcomes in the CNS, our results are consistent with previous
findings that use transgenic models to either ablate scar-forming
astrocytes or knock out specific molecules associated with reac-
tive astrocytes. Ablating scar-forming astrocytes (Bush et al.,
1998, 1999) in models of experimental autoimmune encephalo-
Figure 5. Immune cell infiltration into the GFAP/Vim/PPT1/ CNS. a, CD45, a pan-leukocyte marker, staining in the WT, PPT1/, and GFAP/Vim/PPT1/ cortex. Large
numbers of CD45 cells were observed within the GFAP/Vim/PPT1/ cortex (n 3 per group) compared with either the PPT1/ or WT brains. b–d, At higher magnification, the
CD45 cells appeared to be morphologically similar to microglia (b), granulocytes or macrophages (c), and lymphocytes (d). GFAP/Vim/ staining was indistinguishable from that of WT.
Scale bar, 30m. e, CD3 immunostaining in theWT,GFAP/Vim/, PPT1/, andGFAP/Vim/PPT1/mice. CD3 cellswere found in both the PPT1/ andGFAP/Vim/
PPT1/mice. f, CD68 immunostaining in theWT,GFAP/Vim/, PPT1/, andGFAP/Vim/PPT1/. Immunostainingwith a CD68 antibody demonstrated a largemonocyte
(i.e., microglia and macrophages) population within the PPT1/ and GFAP/Vim/PPT1/ brains, seen here in the cortex, hippocampus, and thalamus (n 3 per group). The CD68
cells were composed of large macrophages and/or activated microglia (inset). g, Quantitation of CD3 immunoreactivity in the WT, GFAP/Vim/, PPT1/, and GFAP/Vim/
PPT1/ brains. There is a significant increase in the number of CD3-positive cells within the GFAP/Vim/PPT1/ and PPT1/ brains when comparedwith controls (n 3 per group).
h, Quantitation of CD68 cells in the WT, GFAP/Vim/, PPT1/, and GFAP/Vim/PPT1/ brains. There is a significant increase in the number of positive cells within the
GFAP/Vim/PPT1/ brains when compared with PPT1/mice or controls (n 3 per group). One-way ANOVAs followed by Tukey’s post hoc tests were used to determine statistical
significance (***p 0.001). Scale bars: a, 100m; b–d, f, 300m.
Figure 6. Blood–brain barrier integrity in the GFAP/Vim/PPT1/mouse. An Evan’s
blue assay was performed to assess BBB permeability in the GFAP/Vim/PPT1/ brains
compared with WT mice. There was no difference in the amount of Evan’s blue/albumin complex
detected in the brains ofGFAP/Vim/PPT1/ comparedwithWTmice (n 4 per group).
There was an increase in Evan’s blue concentration following an MCAO. Statistical differences were
assessed using a one-wayANOVA followedby a Tukey’spost hoc test (*p0.05).
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Figure 7. Elevated cytokine levels in the GFAP/Vim/PPT1/ brains at 1, 3, and 6months of age. Of 14 cytokines assayed, the concentrations of 12 analytes were elevated at 1, 3, or 6
months of age (n 3 per group). a–i, The cytokines can grossly be divided into three groups based on function: generalized proinflammatory molecules (a, d, g); lymphocyte and/or monocyte
activators (b, e, h); or monocyte activators (c, f, i). a– c, Elevations in cytokine levels at 1 month. At 1 month, the only significant elevations in cytokine levels were observed with two
lymphocyte/monoctyeactivators, oncostatin-MandRANTES.d–f, Elevations in cytokine levels at 3months. Therewasan increase inall proinflammatory (d) and lymphocyte/monocyte (e) cytokines
in the GFAP/Vim/PPT1/ mice at 3 months. Of the six monocyte activators (f ) assayed, there were four molecules (i.e., IP-10, MCP-1, MCP-3, and MCP-5) increased in both the
GFAP/Vim/PPT1/andPPT1/brains.MIP-1was increased in solely theGFAP/Vim/PPT1/brains. Although IP-10was significantly increasedPPT1/brains, the levels
of IP-10 were significantly higher in the GFAP/Vim/PPT1/ brains compared PPT1/. g–i, Elevations in cytokine levels at 6 months. At 6 months, the only increase in cytokine
levels observed was in analytes within the monocyte activator group. Interestingly, both the GFAP/Vim/PPT1/ and PPT1/ brains demonstrated (Figure legend continues.)
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myelitis (Voskuhl et al., 2009), traumatic brain injury (Myer et
al., 2006), and spinal cord injury (Faulkner et al., 2004) resulted
in increased tissue damage, greater infarct size, increased neuro-
degeneration, increased demyelination, and exacerbated neuro-
inflammation. Likewise, mice lacking GFAP and vimentin that
were given ischemic injury (Li et al., 2008), traumatic brain injury
(Pekny et al., 1999; Wilhelmsson et al., 2004), or spinal cord
lesions (Pekny et al., 1999) had increased post-traumatic recovery
time, clinical outcomes, and lesion size. Although each transgenic
model has a unique set of limitations for studying reactive astro-
cytes (i.e., neither GFAP nor vimentin is solely expressed by as-
trocytes), the cumulative results from these studies help further
our understanding of the cellular, molecular, and functional
changes associated with astrocyte activation.
In an effort to investigate the underlying mechanism causing
the accelerated phenotype in GFAP/Vim/PPT1/ mice,
the presence of inflammatory cells within the GFAP/Vim/
PPT1/ brains was investigated. In fact, CD45 leukocytes
were detected in the brains of 6-month-old GFAP/Vim/
PPT1/mice, a phenomenon largely absent in the PPT1/ or
GFAP/Vim/ brains at a comparable age. Interestingly, by 7
months, CD45-positive cells were present in the brains of
PPT1/ mice, demonstrating an aspect of neuroinflammation
previously undocumented. The CD45 cells within the GFAP/
Vim/PPT1/ brains were morphologically diverse, contain-
ing both a large monocyte (CD68) and T-cell (CD3)
population. We hypothesize that early activation of microglia
and infiltration of both macrophages and T cells were contribut-
ing to the accelerated disease course observed in the GFAP/
Vim/PPT1/ mice. Although the vimentin deficiency
interferes with leukocyte and monocyte adhesion and extravasa-
tion (Nieminen et al., 2006), the addition of the PPT1 and GFAP
mutations appeared to counteract this effect and allow increased
cell entry into the CNS.
To examine the possible mechanisms for immune cell entry
into the CNS, our work focused on the blood–brain barrier. In-
terestingly, the astrocytes that first display an increase in GFAP
immunoreactivity appear to be in intimate contact with the vas-
culature. Furthermore, PPT1/ mice appear to have aberrant
PECAM and AQP4 immunostaining, suggesting alterations in
the gliovascular unit. Thus, the ability of a large EB–albumin
complex to enter the brain parenchyma was used to investigate
BBB integrity. No gross perturbation of the BBB was appreciable
in either the GFAP/Vim/PPT1/ or PPT1/mice, find-
ings similar to those previously reported in theGFAP/Vim/
mice (Pekny and Wilhelmsson, 2006).
Given that the BBB is both a physical and molecular barrier,
the molecular signals expressed in the CNS responsible for mi-
croglial activation andmonocyte and leukocyte recruitment were
investigated. At 1 month, there were elevations in two cyto-
kines in the GFAP/Vim/PPT1/ brains compared with
GFAP/Vim/, PPT1/, or WT brains. Similarly, by 3
monthsofage,therewasanincreasein12cytokinesintheGFAP/
Vim/PPT1/ brains compared with elevations in only 4 cy-
tokines in the PPT1/ brains. In most cases, cytokine levels in
3-month-oldGFAP/Vim/PPT1/mice were greater than
those seen in PPT1/ mice. Thus, this finding suggests that
increased cytokine expression could not only be responsible for
the influx of peripheral immune cells into the CNS, but also
might provide an explanation for the accelerated neurodegenera-
tion seen in theGFAP/Vim/PPT1/mice. Further studies
need to be performed to investigate the correlation between neu-
roinflammation and chronic neurodegeneration.
Cytokines with increased expression levels in the GFAP/
Vim/PPT1/ brains can be clustered into three groups based
on their known effects in the CNS. First, at 3 months, there were
increased levels of TNF- and IFN- in the GFAP/Vim/
PPT1/ brains. Both of these proinflammatory molecules are
often elevated in the CNS in response to acute injury or chronic
disease. They are responsible for the activation and regulation of
both resident (i.e., astrocytes andmicroglia) and infiltrating (i.e.,
T cells and macrophages) immune cells. IFN- is known to be a
potent inducer of class II MHC expression in astrocytes, which is
subsequently responsible for the activation of both T cells and
macrophages. Furthermore, production of IFN- can damage
the BBB due to cytotoxic effects on endothelial cells (Chavarria
and Alcocer-Varela, 2004). The elevation of both TNF- and
IFN- in the GFAP/Vim/PPT1/ brains, but not in the
PPT1/ brains, suggests that attenuated astrocyte activation ex-
acerbates neuroinflammation in the CNS. Furthermore, it sug-
gests that this is a widespread phenomenon affecting a variety of
cell types in the CNS, namely astrocytes, microglia/macrophages,
and infiltrating lymphocytes.
The second set of elevated cytokines in the GFAP/Vim/
PPT1/ brains demonstrated the largest fold change (i.e., a
6–20-fold change). In all cases, these cytokines (i.e., IP-10,
MIP1, MIP-2,MCP-1,MCP-3, andMCP-5) are responsible for
the activation and recruitment of microglia and monocytes
within the CNS. Not surprisingly, this upregulation correlated
with an increase in the number of CD68-positive monocytes
found within the GFAP/Vim/PPT1/ brains. These mol-
ecules are not only responsible for the recruitment and activation
of monocytes, but also cause an increase in cytokine expression
within these cells, propagating the neuroinflammatory process.
The final group of cytokines (i.e., oncostatin-M, lymphotac-
tin, GM-CSF, and RANTES) is responsible for the recruitment
and activation of T cells in addition to monocytes. Again, these
data correlate with immunostaining of the GFAP/Vim/
PPT1/ brains that demonstrate the presence ofCD3-positive T
cells within the CNS. One molecule, oncostatin-M, is also ex-
pressed by endothelial cells and facilitates leukocyte adhesion and
rolling necessary for extravasation of cells across the blood–brain
barrier. Oncostatin-M, along with RANTES, were the only two
cytokines upregulated in the GFAP/Vim/PPT1/ brains
at 1 month. Thus, we demonstrate molecular and cellular
changes, which could increase inflammation within the CNS
in the presence of attenuated astrogliosis. We believe this pro-
inflammatory cascade is one explanation for the accelerated
neurodegeneration and premature death of GFAP/Vim/
PPT1/mice.
The generation of the GFAP/Vim/PPT1/ mice
helped elucidate the profound neuroinflammatory component
in INCL. Although previous research described the presence of
both reactive astrocytes and microglia (Bible et al., 2004; Griffey
et al., 2004, 2006; Kielar et al., 2007; Macauley et al., 2009) and
increasedmRNA levels of a number of cytokines and chemokines
4
(Figure legend continued.) a significant increase in IP-10, MIP-2, MCP-1, MCP-3, andMCP-5.
In three of the four molecules, the concentrations of cytokines were higher in the PPT1/
brains compared with GFAP/Vim/PPT1/ brains. Using one-way ANOVAs followed
by Bonferroni’s post hoc tests, the asterisk (*) indicates a significant increase at the p 0.05
level of one group compared with all other groups, while the bar indicates no significant
difference between two groups. Checked bars indicate WT, diagonal hatch marks indicate
GFAP/Vim/, open bars indicate PPT1/, and filled bars indicate GFAP/Vim/
PPT1/ brains.
Macauley et al. • Reactive Astrocytes in INCL J. Neurosci., October 26, 2011 • 31(43):15575–15585 • 15583
in PPT1/ brains (Qiao et al., 2007), the scope of neuroinflam-
mation in INCL has largely gone underappreciated. The severity
of the immune cell activation and recruitment in the GFAP/
Vim/PPT1/mice illustrates the need to further understand
this pathogenic mechanism so that all aspects of CNS disease are
properly targeted therapeutically in INCL.
Returning to the question, “are reactive astrocytes beneficial
or deleterious in INCL?,” this study investigated the role of atten-
uated astrocyte activation in a mouse model of chronic neurode-
generation using the GFAP/Vim/ mice. To date, astrocyte
activation has largely been studied in models of acute trauma or
injury. Findings from those studies demonstrate a complex re-
sponse of both positive and negative outcomes. Our data are
consistent with these previous studies in that reactive astrocytes
are protective in INCL. This study is of particular interest be-
cause, in contrast to most other models used to define reactive
astrocytes, INCL is one of the few models where GFAP upregu-
lation is a widespread phenomenon, glial scarring of small lesions
or infarcts is absent, CNS disease is both chronic and progressive,
and the disease-causing mechanism (i.e., PPT1 deficiency) re-
mains present for the duration of life. Given this unique set of
characteristics, these data help further the understanding of reac-
tive astrocytes in yet another example of CNS disease. This has
important implications not only for our understanding and
treatment of INCL, but also for our understanding of the com-
plicated relationship between intermediate filament upregula-
tion, reactive astrocytes, and neurodegeneration in other chronic
neurodegenerative disorders, like AD, PD, or ALS.
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